226 related articles for article (PubMed ID: 24720338)
1. PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine.
Israel I; Richter D; Stritzker J; van Ooschot M; Donat U; Buck AK; Samnick S
Curr Cancer Drug Targets; 2014; 14(4):371-9. PubMed ID: 24720338
[TBL] [Abstract][Full Text] [Related]
2. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
3. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
Li ZB; Chen K; Chen X
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.
Liu Z; Niu G; Shi J; Liu S; Wang F; Liu S; Chen X
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):947-57. PubMed ID: 19159928
[TBL] [Abstract][Full Text] [Related]
6. MicroPET/CT imaging of αvβ₃ integrin via a novel ⁶⁸Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction.
Menichetti L; Kusmic C; Panetta D; Arosio D; Petroni D; Matteucci M; Salvadori PA; Casagrande C; L'Abbate A; Manzoni L
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1265-74. PubMed ID: 23674206
[TBL] [Abstract][Full Text] [Related]
7. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
[TBL] [Abstract][Full Text] [Related]
8.
Chen CJ; Chan CH; Lin KL; Chen JH; Tseng CH; Wang PY; Chien CY; Yu HM; Lin WJ
Nucl Med Biol; 2019; 68-69():22-30. PubMed ID: 30578136
[TBL] [Abstract][Full Text] [Related]
9. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.
Liu Z; Niu G; Wang F; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1483-94. PubMed ID: 19360404
[TBL] [Abstract][Full Text] [Related]
10. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃.
Notni J; Pohle K; Wester HJ
Nucl Med Biol; 2013 Jan; 40(1):33-41. PubMed ID: 22995902
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
13. [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.
Knetsch PA; Petrik M; Rangger C; Seidel G; Pietzsch HJ; Virgolini I; Decristoforo C; Haubner R
Nucl Med Biol; 2013 Jan; 40(1):65-72. PubMed ID: 23102540
[TBL] [Abstract][Full Text] [Related]
14. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
15. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
16. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
17. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice.
Lang L; Li W; Guo N; Ma Y; Zhu L; Kiesewetter DO; Shen B; Niu G; Chen X
Bioconjug Chem; 2011 Dec; 22(12):2415-22. PubMed ID: 22026940
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2.
Gao H; Lang L; Guo N; Cao F; Quan Q; Hu S; Kiesewetter DO; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):683-92. PubMed ID: 22274731
[TBL] [Abstract][Full Text] [Related]
19. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model.
Guo N; Lang L; Li W; Kiesewetter DO; Gao H; Niu G; Xie Q; Chen X
PLoS One; 2012; 7(5):e37506. PubMed ID: 22624041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
